$4.75
+0.15(3.38%)
Mkt Cap $444M
$3.84
$8.45
52-Week Range
At A Glance
1
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally.
2
Revenue is primarily driven by Hereditary Cancer (44.1%) and Prenatal (21.3%).
3
Most recently: and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth (2026-02-23).
$444M
Market Cap
$826M
Revenue
-$367M
Net Income
Employees2,700
Fundamentals
How The Business Makes Money
Revenue by Segment
Hereditary Cancer44.1%($2.1B)
Prenatal21.3%($1.0B)
Mental Health18.7%($906M)
Tumor Profiling15.9%($766M)
Revenue by Geography
US91.5%($4.4B)
Non Us8.5%($412M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000899923
ISINUS62855J1043
CUSIP62855J104
Phone801 584 3600
Address320 Wakara Way, Salt Lake City, UT, 84108, US
SEC EDGAR